JPMorgan Chase & Co. Reaffirms Underweight Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “underweight” rating reissued by equities research analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports.

A number of other equities analysts have also recently commented on the stock. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,100 ($26.56) target price on shares of GSK in a research report on Thursday, June 27th. Barclays reiterated an “equal weight” rating and issued a GBX 1,725 ($21.82) target price on shares of GSK in a research report on Tuesday, May 7th. Citigroup reiterated a “buy” rating and issued a GBX 2,100 ($26.56) target price on shares of GSK in a research report on Monday, June 24th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 1,950 ($24.66) target price on shares of GSK in a research report on Friday, June 28th. Finally, Shore Capital reiterated a “buy” rating on shares of GSK in a research report on Thursday, June 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of GBX 1,791.25 ($22.66).

GSK Stock Performance

LON GSK opened at GBX 1,503.50 ($19.02) on Tuesday. GSK has a 52-week low of GBX 1,302.60 ($16.48) and a 52-week high of GBX 1,823.50 ($23.06). The company has a debt-to-equity ratio of 134.34, a quick ratio of 0.73 and a current ratio of 0.87. The company has a market capitalization of £61.34 billion, a P/E ratio of 1,373.85, a P/E/G ratio of 1.19 and a beta of 0.27. The company has a fifty day moving average of GBX 1,680.62 and a 200-day moving average of GBX 1,633.33.

Insider Buying and Selling at GSK

In other news, insider Wendy Becker acquired 446 shares of the firm’s stock in a transaction on Thursday, June 20th. The shares were purchased at an average price of GBX 1,614 ($20.41) per share, for a total transaction of £7,198.44 ($9,105.03). Corporate insiders own 1.60% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.